Last edition
News about "Biotechnology"
Novo Holdings Completes Acquisition of Catalent
With the completion of the transaction, holders of Catalent common stock are entitled to receive USD 63.50 per share in cash, representing a premium of approximately 47.5 percent to the 60-day volume-weighted average price as of February 2, 2024.
Biotechnology | 20/12/2024 | By Aishwarya
Ampersand Capital Partners Launches Newly Branded Business Gannet BioChem
The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama.
Biotechnology | 03/12/2024 | By Aishwarya
NRx Pharmaceuticals Welcomes Michael Abrams as Chief Financial Officer
Abrams succeeds Interim-CFO Richard Narido, who will continue to support the Company's financial function and other projects.
Biotechnology | 19/11/2024 | By Aishwarya
BioIVT Acquires ZenBio to Expand its Pharmaceutical Portfolio
Together, BioIVT and ZenBio will offer an expanded portfolio of skin-based expertise, primary cell and exosome isolation, as well as blood products for pharmaceutical and cosmetics companies.
Biotechnology | 26/08/2024 | By Aishwarya
Vivint Pharma to Invest INR 400 Crores in New Injectables Facility in Hyderabad
The company will be investing INR 400 crores in the new facility with the potential to employ 1000 people, further solidifying Telangana’s position as a global hub for life sciences.
Biotechnology | 09/08/2024 | By Aishwarya | 246
Lupin Gets EIR from US FDA for its Somerset Manufacturing Facility
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its manufacturing facility in Somerset.
Biotechnology | 24/06/2024 | By Aishwarya | 165
Lupin Gets Tentative Approval from US FDA for Letermovir Tablets
Lupin has secured a tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Letermovir Tablets, 240 mg and 480 mg, to market a generic equivalent of Prevymis Tablets, 240 mg and 480 mg, of Merck Sharp & Dohme LLC.
Biotechnology | 05/06/2024 | By Aishwarya | 332
H.E.L Group Expands its Sales Newtowk with Addition of Two Specialist Distributors
H.E.L Group (H.E.L) has expanded its global sales network with the appointment of two distributors: Paralab and ProAnalytics.
Biotechnology | 30/05/2024 | By Aishwarya
Integral Molecular Gains ISO 9001 Certification for its MPA Services
Integral Molecular has secured IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array (MPA) specificity testing services.
<br />
Biotechnology | 28/03/2024 | By Manvi | 301
Novartis to invest $300 M in biologics manufacturing and development operations
The company plans to establish a biologics hub at its Basel, Switzerland campus
Biotechnology | 14/09/2022 | By Sudeep Soparkar | 472
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy